Cargando…

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

BACKGROUND: N-terminally truncated and modified pyroglutamate-3 amyloid-β protein (pE3-Aβ) is present in most, if not all, cerebral plaque and vascular amyloid deposits in human Alzheimer's disease (AD). pE3-Aβ deposition is also found in AD-like transgenic (tg) mouse brain, albeit in lesser qu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frost, Jeffrey L., Liu, Bin, Kleinschmidt, Martin, Schilling, Stephan, Demuth, Hans-Ulrich, Lemere, Cynthia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2012
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702016/ https://www.ncbi.nlm.nih.gov/pubmed/22343072 http://dx.doi.org/10.1159/000335913

Ejemplares similares

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
por: Crehan, Helen, et al.
Publicado: (2020)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
por: Schilling, Stephan, et al.
Publicado: (2018)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease
por: Zagorski, Karen, et al.
Publicado: (2023)

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2011)

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
por: Vukicevic, M., et al.
Publicado: (2022)

N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity
por: Kehlen, Astrid, et al.
Publicado: (2017)

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
por: Hettmann, Thore, et al.
Publicado: (2020)

Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol
por: Dammers, Christina, et al.
Publicado: (2015)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
por: Gnoth, Kathrin, et al.
Publicado: (2020)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease
por: Minami, S Sakura, et al.
Publicado: (2010)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Strategy to enhance transgene expression in proximity of amyloid plaques in a mouse model of Alzheimer's disease
por: Weber-Adrian, Danielle, et al.
Publicado: (2019)

Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques
por: Hashimoto, Tadafumi, et al.
Publicado: (2020)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
por: Tanghe, An, et al.
Publicado: (2010)

Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased Aβ Plaque Accumulation in a Mouse Model of Alzheimer’s Disease
por: Cherry, Jonathan D., et al.
Publicado: (2012)

Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer’s disease
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2019)

Lack of α-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease
por: Kallhoff, Verena, et al.
Publicado: (2007)

Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer’s disease
por: Park, Sohui, et al.
Publicado: (2021)

Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
por: De Kimpe, Line, et al.
Publicado: (2012)

Role of the Fast Kinetics of Pyroglutamate-Modified Amyloid-β Oligomers in Membrane Binding and Membrane Permeability
por: Lee, Joon, et al.
Publicado: (2014)

Memory deficiency, cerebral amyloid angiopathy, and amyloid-β plaques in APP+PS1 double transgenic rat model of Alzheimer’s disease
por: Klakotskaia, Diana, et al.
Publicado: (2018)

Immunotherapy for Alzheimer’s disease: hoops and hurdles
por: Lemere, Cynthia A
Publicado: (2013)

Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine
por: Hayes, Crystal D, et al.
Publicado: (2013)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2015)

Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging
por: Wadghiri, Youssef Zaim, et al.
Publicado: (2013)

Intranasal Delivery of Collagen-Loaded Neprilysin Clears Beta-Amyloid Plaques in a Transgenic Alzheimer Mouse Model
por: Humpel, Christian
Publicado: (2021)

Tetramodal Chemical Imaging Delineates the Lipid–Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer’s Disease Models
por: Ge, Junyue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_43ifqkl2mbp51ohtt7bt3udih4